Advertisement
DRUG vs ESLA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a Hold and ESLA is a Hold.
DRUG in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 02, 2026
DRUG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where DRUG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +16.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where DRUG advanced for three days, in 155 of 188 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DRUG as a result. In 83 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for DRUG turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 39 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRUG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DRUG entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.733) is normal, around the industry mean (3.498). P/E Ratio (-8.099) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. DRUG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRUG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ESLA in +99.09% Uptrend, advancing for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ESLA advanced for three days, in 124 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 71 cases where ESLA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
ESLA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ESLA crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for ESLA moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 18 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ESLA as a result. In 67 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.
The Moving Average Convergence Divergence Histogram (MACD) for ESLA turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 29 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
ESLA broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ESLA entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.197) is normal, around the industry mean (3.498). P/E Ratio (-1.501) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ESLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| DRUG | ESLA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 55% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 68% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 58% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 51% |
| Advances ODDS (%) | 3 days ago 82% | 2 days ago 83% |
| Declines ODDS (%) | 8 days ago 90% | 6 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 58% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DRUG’s FA Score shows that 2 FA rating(s) are green while ESLA’s FA Score has 2 green FA rating(s).
- DRUG’s FA Score: 2 green, 3 red.
- ESLA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DRUG’s TA Score shows that 4 TA indicator(s) are bullish while ESLA’s TA Score has 4 bullish TA indicator(s).
- DRUG’s TA Score: 4 bullish, 4 bearish.
- ESLA’s TA Score: 4 bullish, 6 bearish.
Price Growth
DRUG (@Biotechnology) experienced а +4.92% price change this week, while ESLA (@Biotechnology) price change was +78.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
DRUG is expected to report earnings on Dec 22, 2026.
ESLA is expected to report earnings on Dec 02, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
DRUG and
Correlation & Price change
A.I.dvisor indicates that over the last year, DRUG has been loosely correlated with KPTI. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if DRUG jumps, then KPTI could also see price increases.
| Ticker / NAME | Correlation To DRUG | 1D Price Change % | ||
|---|---|---|---|---|
| DRUG | 100% | -6.22% | ||
| KPTI - DRUG | 56% Loosely correlated | -56.50% | ||
| MDXG - DRUG | 40% Loosely correlated | +1.51% | ||
| BIVI - DRUG | 39% Loosely correlated | -2.31% | ||
| PTHS - DRUG | 38% Loosely correlated | -5.02% | ||
| PGEN - DRUG | 37% Loosely correlated | -4.44% | ||
More | ||||
ESLA and
Correlation & Price change
A.I.dvisor tells us that ESLA and DRUG have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESLA and DRUG's prices will move in lockstep.
| Ticker / NAME | Correlation To ESLA | 1D Price Change % | ||
|---|---|---|---|---|
| ESLA | 100% | +45.40% | ||
| DRUG - ESLA | 28% Poorly correlated | -6.22% | ||
| KPTI - ESLA | 27% Poorly correlated | -56.50% | ||
| PRLD - ESLA | 25% Poorly correlated | N/A | ||
| RXRX - ESLA | 24% Poorly correlated | -6.70% | ||
| HUMA - ESLA | 23% Poorly correlated | +29.61% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CNAV | 36.31 | 0.01 | +0.03% |
| Mohr Company Nav ETF (CNAV) | |||
| CTEF | 79.80 | N/A | N/A |
| Castellan Targeted Equity ETF (CTEF) | |||
| SPYT | 16.22 | -0.04 | -0.25% |
| Defiance S&P 500 Target Income ETF (SPYT) | |||
| JGLO | 71.05 | -0.35 | -0.49% |
| JPMorgan Global Select Equity ETF Global Select Equity ETF (JGLO) | |||
| RKLZ | 13.42 | -2.01 | -13.03% |
| Defiance Daily Target 2x Short RKLB ETF (RKLZ) | |||